REPL: Replimune Corp Net earnings per share (EPS TTM)
High barriers to entry in the biolaboratory sector limit competition within the viral platform niche. Replimune Group, Inc. (REPL) relies on its own cGMP center in the US, which ensures sterility and stability of drug supplies. The 12-month net income per share history confirms the financial dynamics, where the mark -2.94 characterizes this parameter. Management is currently adapting the structure in anticipation of upcoming clinical trial results.
Summary analytical data breakdowns for Replimune Group Inc (REPL)
- share price and expert price forecast:
- market capitalization information:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Replimune Group, Inc.|REPL - Long-Term Debt to Capital|Short-Term Debt to Equity Replimune Corp|REPL - Company Aggregate Debt|Debt to Book Capitalization Ratio Replimune Group, Inc.|REPL - Long-Term Debt|Company Current Liabilities Replimune|Quick Liquidity Indicator replimune.com
- earnings and multiples data:
REPL - Profit After Payment of Taxes|Projected Future Earnings Replimune Group, Inc.|REPL - Company Value to Net Income|Forward P/E Multiple Replimune|REPL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Replimune Group, Inc.|REPL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Replimune|REPL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months replimune.com|REPL - Earnings per share trend in current year|Expected earnings per share growth for next year Replimune Group, Inc.
Fundamental valuation:REPL - Replimune Group, Inc.
While Replimune Group, Inc. (REPL) management adapts its structure to clinical trial results and the R&D roadmap, the company's financial stability depends on capital efficiency. The rolling annual net income per share, which has reached -2.94, measures equity income adjusted for issuance volume, allowing investors to identify one-time anomalies in the fundamental results of this high-risk biopharmaceutical asset.
Main competitors
IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|LYEL - Earnings per share for the last twelve months|IPHA (Innate Pharma S.A) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma)|Earnings per share for the trailing year ALXO|Cue Biopharma, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months PDS Biotechnology|sonnetbio.com (SONN) - Earnings per share for the last twelve months|MAIA Bio - Earnings per share for the trailing year|LIMN (Liminatus Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Lava Tx|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|TOVX - Earnings per share for the last twelve months|Earnings per share for the trailing year GRTS (Gritstone bio, Inc.)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune Inc (NEXI)|Earnings per share for the last twelve months Turnstone Biologics Corp|Vaccinex Inc - Earnings per one share for the last 12 months|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)
